These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 19751153

  • 1. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States.
    Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J.
    J Infect Dis; 2009 Oct 15; 200(8):1311-7. PubMed ID: 19751153
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health.
    de Vries R, Klok RM, Brouwers JR, Postma MJ.
    Vaccine; 2009 Feb 05; 27(6):846-52. PubMed ID: 19084566
    [Abstract] [Full Text] [Related]

  • 3. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen VL, Mehta J, Colborn DK, Lieu TA.
    Pediatrics; 2009 Jun 05; 123(6):1452-63. PubMed ID: 19482754
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
    Lee YC, Lin JT, Wu HM, Liu TY, Yen MF, Chiu HM, Wang HP, Wu MS, Hsiu-Hsi Chen T.
    Cancer Epidemiol Biomarkers Prev; 2007 May 05; 16(5):875-85. PubMed ID: 17507609
    [Abstract] [Full Text] [Related]

  • 5. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology.
    Rupnow MF, Owens DK, Shachter R, Parsonnet J.
    Helicobacter; 1999 Dec 05; 4(4):272-80. PubMed ID: 10597398
    [Abstract] [Full Text] [Related]

  • 6. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB, Wittenborn JS, Lee PP, Wirth KE, Sorensen SW, Hoerger TJ, Saaddine JB.
    Ophthalmology; 2009 May 05; 116(5):823-32. PubMed ID: 19285730
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB, Cooksley CD, Geraci JM, Bekele BN, Cantor SB, Rolston KV, Elting LS.
    Cancer; 2007 Jun 01; 109(11):2357-64. PubMed ID: 17457827
    [Abstract] [Full Text] [Related]

  • 8. [The cost-effectiveness of pneumococcal vaccination in Catalonia].
    Plans Rubió P, Garrido Morales P, Salleras Sanmartí L.
    Rev Esp Salud Publica; 1995 Jun 01; 69(5):409-17. PubMed ID: 8564860
    [Abstract] [Full Text] [Related]

  • 9. Retrospective cost-effectiveness analyses for polio vaccination in the United States.
    Thompson KM, Tebbens RJ.
    Risk Anal; 2006 Dec 01; 26(6):1423-40. PubMed ID: 17184390
    [Abstract] [Full Text] [Related]

  • 10. [Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis].
    Wang Q, Jin PH, Lin GW, Xu SR, Chen J.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb 01; 24(2):135-9. PubMed ID: 12697117
    [Abstract] [Full Text] [Related]

  • 11. Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada.
    Xie F, O'Reilly D, Ferrusi IL, Blackhouse G, Bowen JM, Tarride JE, Goeree R.
    J Am Coll Radiol; 2009 May 01; 6(5):317-23. PubMed ID: 19394572
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps.
    Vold Pepper P, Owens DK.
    Clin Infect Dis; 2000 Jan 01; 30(1):157-64. PubMed ID: 10619745
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese.
    Xie F, Luo N, Blackhouse G, Goeree R, Lee HP.
    Int J Technol Assess Health Care; 2008 Jan 01; 24(1):87-95. PubMed ID: 18218173
    [Abstract] [Full Text] [Related]

  • 14. Helicobacter pylori vaccine development: optimisation of strategies and importance of challenging strain and animal model.
    Hoffelner H, Rieder G, Haas R.
    Int J Med Microbiol; 2008 Jan 01; 298(1-2):151-9. PubMed ID: 17714988
    [Abstract] [Full Text] [Related]

  • 15. Towards the development of vaccines against Helicobacter pylori: status and issues.
    Del Giudice G.
    Curr Opin Investig Drugs; 2001 Jan 01; 2(1):40-4. PubMed ID: 11527009
    [Abstract] [Full Text] [Related]

  • 16. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH.
    Vaccine; 2007 Jul 20; 25(29):5433-40. PubMed ID: 17560695
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.
    Vaccine; 2008 Jun 02; 26(23):2841-8. PubMed ID: 18462851
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States.
    Rein DB, Hicks KA, Wirth KE, Billah K, Finelli L, Fiore AE, Hoerger TJ, Bell BP, Armstrong GL.
    Pediatrics; 2007 Jan 02; 119(1):e12-21. PubMed ID: 17200237
    [Abstract] [Full Text] [Related]

  • 19. Systemic immunization with unadjuvanted whole Helicobacter pylori protects mice against heterologous challenge.
    Harbour SN, Every AL, Edwards S, Sutton P.
    Helicobacter; 2008 Dec 02; 13(6):494-9. PubMed ID: 19166414
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background.
    Sutton P, Doidge C, Pinczower G, Wilson J, Harbour S, Swierczak A, Lee A.
    FEMS Immunol Med Microbiol; 2007 Jul 02; 50(2):213-9. PubMed ID: 17567282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.